Cargocytes are engineered allogenic cell lines that can carry a variety of payloads like small molecule compounds, gene editing therapies, therapeutic RNAs, and powerful biologics such as immune modulating cytokines, antibodies and oncolytic viruses.
Adoptive Cellular Therapies, such as Tumor Infiltrating Lymphocytes and T cells expressing Chimeric Antigen Receptors, are currently being tested and used to treat blood cancers, but do not work well on solid tumors.
They are also hindered by the need for a specific antigen target, long development times, adverse patient reactions, rapid degradation and a complex manufacturing process.
Cytonus Therapeutics Inc. is a spinout biotechnology company based on work done by founder and CSO Richard Klemke, Ph.D., professor of pathology at University of California San Diego School of Medicine.
Each year, more than 44,000 people in the US die from Pancreatic Cancer and 55,000 new cases are diagnosed. Most survive just five to six months after diagnosis because less than 10 % are diagnosed early enough where a surgical removal can be curative.
Despite some amazing scientific advancements in medicine, no one has been able to move the needle on the survival rates for Pancreatic Cancer in the past 40 years.
As a platform technology, Cargocyte has many therapeutic applications and will be commercialised through a blend of internal and partnered programmes.
Cytonus Therapeutics is a biopharmaceutical company developing a next-generation Adoptive Cellular Transport platform called Cargocytes.
The San Diego-based company's proprietary Cargocyte platform are cellular-engineered transporters of a multiplicity of therapeutic payloads to tissue in a selective, controllable and potent off-the-shelf cellular therapy for the potential treatment of several disease across multiple therapeutic areas.
Cytonus' initial focus is to advance Cargocyte candidates for the treatment of rare and difficult to treat cancers and inflammatory diseases.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins
Zymedi commences first in human dosage of ZMA001
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
EicOsis Human Health commences EC5026 Phase 1b multiple-ascending dose clinical trial
Takeda's HyQvia approved for maintenance therapy in CIDP patients
Celltrion USA submits CT-P47 Biologics License Application to FDA
Formosa Pharmaceuticals agrees licensing deal in Brazil for APP13007